glutamine has been researched along with cabozantinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Dang, R; Emberley, E; Gross, M; Huang, T; Li, W; MacKinnon, A; Pan, A; Parlati, F; Singh, D; Sotirovska, N; Steggerda, SM; Wang, T | 1 |
| Agarwal, N; Akella, L; Appleman, LJ; Davis, N; Escudier, B; Figlin, R; Gandhi, S; Geynisman, DM; Goodman, O; Iacovelli, R; Jain, RK; Lawrence, NJ; Lee, RJ; McGregor, B; Mellado, B; Motzer, R; Orford, K; Porta, C; Powles, T; Sepúlveda Sánchez, JM; Stadler, WM; Tannir, NM | 1 |
2 other study(ies) available for glutamine and cabozantinib
| Article | Year |
|---|---|
The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Topics: Anilides; Animals; Benzeneacetamides; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Everolimus; Female; Gene Expression Regulation, Neoplastic; Glucose; Glutaminase; Glutamine; Humans; Kidney Neoplasms; Mice; Pyridines; Signal Transduction; Thiadiazoles; Xenograft Model Antitumor Assays | 2021 |
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Double-Blind Method; Female; Glutamates; Glutaminase; Glutamine; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Male; Middle Aged; Nivolumab; Protein Kinase Inhibitors | 2022 |